Roche ASR Marketing Approach For AmpliChip Microarray Draws FDA Scrutiny
This article was originally published in The Gray Sheet
Executive Summary
CDRH is asserting that Roche's AmpliChip CYP450 microarray, launched June 25, does not qualify as an analyte-specific reagent, and may require premarket review